9 results on '"ncic"'
Search Results
2. Banishing justice: Extradition limits in the United States.
- Author
-
Bierie, David M. and Budd, Kristen M.
- Subjects
- *
WARRANTS (Law) , *DISCRETION , *FUGITIVES from justice , *EXILE (Punishment) , *VOTING , *UNITED States presidential election, 2016 - Abstract
Arrest warrants are an important and pervasive aspect of crime and justice in the United States. There are nearly three million arrest warrants active on any given day, of which several hundred thousand were issued for serious violent crimes (SVCs) such as aggravated assault, robbery, forcible sexual assault, and homicide. In more than a third of those SVC warrants, however, extradition is conditionally waived such that an offender can avoid arrest by leaving town; they can elect banishment over prosecution. Studying extradition limits among these serious offenses presents an opportunity to illuminate both a challenge to public safety and justice, as well as forces underlying discretionary decision making by police. To that end, we study all arrest warrants issued in the United States for SVCs between 2017 and 2019. We model banishment rates at the county‐level within a multivariate negative binomial framework. Analyses showed banishment varied as a function of policing capacity, firearm use in crimes, racial composition, and voting behavior during the 2016 presidential election. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients
- Author
-
Paff, Michelle, Alexandru-Abrams, Daniela, Hsu, Frank PK, and Bota, Daniela A
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Immunology ,Brain Cancer ,Immunization ,Brain Disorders ,Cancer ,Rare Diseases ,Orphan Drug ,Neurosciences ,Evaluation of treatments and therapeutic interventions ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,6.1 Pharmaceuticals ,Animals ,Antibodies ,Monoclonal ,Humanized ,Antineoplastic Combined Chemotherapy Protocols ,Bevacizumab ,Blood-Brain Barrier ,Brain Neoplasms ,Camptothecin ,Cancer Vaccines ,Chemoradiotherapy ,Dacarbazine ,Disease-Free Survival ,ErbB Receptors ,Glioblastoma ,Humans ,Immunotherapy ,Irinotecan ,Mice ,Temozolomide ,Vaccination ,Vaccines ,Subunit ,brain ,EGFRVIII ,glioblastoma ,therapies ,vaccine ,EGFRvIII ,The epidermal growth factor receptor variant III ,GBM ,Glioblastoma Multiforme ,WHO ,World Health Organization ,Y ,year ,SEER ,Surveillance ,Epidemiology ,and End Results Program ,VEGF ,Vascular endothelial growth factor ,CPT-11 ,irinotecan ,Camptosar ,OS ,overall survival ,PFS ,progression-free survival ,EORTC ,European Organization for Research and Treatment of Cancer ,NCIC ,National Cancer Institute of Canada ,CNS ,central nervous system ,APC ,antigen-presenting cell ,MHC ,major histocompatibility complex ,BBB ,blood brain barrier ,LPS ,lipopolysaccharide ,D ,day ,Ab ,antibody ,TGF-b ,transforming growth factor beta ,IL-10 ,Interleukin-10 ,PGE2 ,prostaglandin E2 ,Treg cells ,regulatory T cells ,TH2 cells ,T helper type 2 cells ,CD4 ,cluster of differentiation 4 ,CD25 ,cluster of differentiation 25 ,IL-2 ,Interleukin-2 ,GAGE ,G antigen gene family ,Ras ,rat sarcoma genes ,Grb2 ,Growth factor receptor-bound protein 2 ,KLH ,keyhole limpet hemocyanin ,CTL ,Cytotoxic T lymphocytes ,HLA ,human leukocyte antigen ,DTH ,delayed-type hypersensitivity ,ACTIVATE ,A Complementary Trial of an Immunotherapy Vaccine against Tumor Specific EGRFvIII ,TMZ ,temozolomide ,KPS ,Karnofsky performance status ,TTP ,time to progression ,GM-CSF ,Granulocyte-macrophage colony-stimulating factor ,MGMT ,O-6-methylguanine-DNA methyltransferase ,INF-g ,Interferon gamma ,IL-12 ,Interleukin-12 ,ACTIVATE ,A Complementary Trial of an Immunotherapy Vaccine against Tumor Specific EGRFvIII ,APC ,antigen-presenting cell ,Ab ,antibody ,BBB ,blood brain barrier ,CD25 ,cluster of differentiation 25 ,CD4 ,cluster of differentiation 4 ,CNS ,central nervous system ,CPT-11 ,irinotecan ,Camptosar ,CTL ,Cytotoxic T lymphocytes ,D ,day ,DTH ,delayed-type hypersensitivity ,EGFRvIII ,The epidermal growth factor receptor variant III ,EORTC ,European Organization for Research and Treatment of Cancer ,GAGE ,G antigen gene family ,GBM ,Glioblastoma Multiforme ,GM-CSF ,Granulocyte-macrophage colony-stimulating factor ,Grb2 ,Growth factor receptor-bound protein 2 ,HLA ,human leukocyte antigen ,IL-10 ,Interleukin-10 ,IL-12 ,Interleukin-12 ,IL-2 ,Interleukin-2 ,INF-g ,Interferon gamma ,KLH ,keyhole limpet hemocyanin ,KPS ,Karnofsky performance status ,LPS ,lipopolysaccharide ,MGMT ,O-6-methylguanine-DNA methyltransferase ,MHC ,major histocompatibility complex ,NCIC ,National Cancer Institute of Canada ,OS ,overall survival ,PFS ,progression-free survival ,PGE2 ,prostaglandin E2 ,Ras ,rat sarcoma genes ,SEER ,Surveillance ,Epidemiology ,and End Results Program ,TGF-b ,transforming growth factor beta ,TH2 cells ,T helper type 2 cells ,TMZ ,temozolomide ,TTP ,time to progression ,Treg cells ,regulatory T cells ,VEGF ,Vascular endothelial growth factor ,WHO ,World Health Organization ,Y ,year ,Medical Microbiology ,Pharmacology and Pharmaceutical Sciences ,Virology ,Medical biotechnology ,Medical microbiology - Abstract
Glioblastoma Multiforme (GBM) is the most common type of brain tumor and it is uniformly fatal. The community standard of treatment for this disease is gross or subtotal resection of the tumor, followed by radiation and temozolomide. At recurrence bevacizumab can be added for increased progression free survival. Many challenges are encountered while trying to devise new drugs to treat GBM, such as the presence of the blood brain barrier which is impermeable to most drugs. Therefore in the past few years attention was turned to immunological means for the treatment of this devastating disease. EGFRvIII targeting has proven a good way to attack glioblastoma cells by using the immune system. Although in still in development, this approach holds the promise as a great first step toward immune-tailored drugs for the treatment of brain cancers.
- Published
- 2014
4. Recognizability of computer-generated facial approximations in an automated facial recognition context for potential use in unidentified persons data repositories: Optimally and operationally modeled conditions.
- Author
-
Parks, Connie L. and Monson, Keith L.
- Subjects
- *
FACE perception , *COMPUTER-generated imagery , *APPROXIMATION theory , *COMPUTER software , *IMAGE analysis , *FACIAL anatomy , *BIOMETRY , *DATABASES , *FORENSIC anthropology , *DIGITAL image processing - Abstract
Currently in the United States, the remains of thousands of unidentified human decedents are housed in medical, law enforcement, and forensic facilities throughout the country. A number of digital data repositories have been established to curate and disseminate the details of these unidentified decedent cases; some repositories also maintain records of missing persons. Although a cross-reference for textual data similarity occurs between the missing persons and unidentified decedent records in some repositories, no repository is currently known to employ an image analysis technology for cross-referencing image data. Results suggest that the computer-generated facial approximations used in this research were consistently included in prioritized candidate lists when used in an automated facial recognition context. Two concurrent studies exploring the specific use-case discussed here were executed. The first employed an optimally-conditioned facial image gallery (g=6159) (i.e., a gallery comprised of highly consistent facial images), a research design intended to establish the ceiling performance of the combined use of the two software programs employed. The second employed a gallery (g=1816) compiled from a real-world dataset of missing persons' facial images, a research design intended to inform potential operational performance when using the highly varied facial images typically comprising public databases. Multiple types of facial approximations (reconstructions) with varying degrees of weight adjustments, age adjustments, or the presence (or absence) of visible eyes, and combinations of these variables, were evaluated. Overall, in the larger, optimally modeled study, 53% of the facial approximations for the t=159 test subjects examined were matched to his or her corresponding life photo within the top 50 images of a candidate list generated from a blind (unrestricted) search of the highly consistent gallery (g=6159). In the operationally modeled study, 31% of the test subjects' (t=16) facial approximations were matched to their corresponding life photos within the top 50 images of a candidate list generated from a blind search of the gallery populated with images from an operational dataset (g=1816). As anticipated, candidate list inclusion rates improved with the use of demographic filters. No significantly different inclusion rates were observed between the sex or age cohorts examined. Significant differences were, however, observed across population cohorts. Entities curating missing and unidentified decedent records may benefit from a paired implementation of facial recognition technology and computer-generated approximations as part of a comprehensive investigative strategy for the specific envisioned use-case discussed in this research. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Time to Apprehension and the Correlates of Warrant Closure.
- Author
-
Craun, Sarah W. and Tiedt, Andrew D.
- Subjects
- *
SEX crimes , *WARRANTS (Law) , *SEX offenders , *SENSORY perception , *PROPORTIONAL hazards models - Abstract
To understand how offenders are caught, past research has focused on case closures, which combines the identification and apprehension of a fugitive. However, there is a gap in applied research concerning duration to apprehension and variation in time to capture by crime. This study examined the days to close arrest warrants using administrative data containing 1.3 million cases. A Cox proportional hazards model demonstrated that sex crimes involving contact or encompassing child pornography/exploitation, kidnapping, sex offender registration violations, and warrants involving assaults or an armed/dangerous notation had the strongest relationships to warrant closure. The results illustrate the prioritizing of cases involving sex offenders and violent offenders, as well as underscoring a need for future research on time to warrant closure. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185
- Author
-
Rena Buckstein, James Joseph Biagi, Scott A. Laurie, Helen Mackay, Ralph M. Meyer, Eric L. Eisenhauer, and Lesley Seymour
- Subjects
Oncology ,Pathology ,medicine.medical_specialty ,Angiogenesis ,PDGFRB ,PDGFRA ,Metastasis ,angiogenesis ,chemistry.chemical_compound ,Primary peritoneal carcinoma ,ind ,Internal medicine ,Sunitinib ,medicine ,ncic ,receptor tyrosine kinase inhibitor ,business.industry ,Cancer ,phase ii ,medicine.disease ,Vascular endothelial growth factor ,chemistry ,business ,Canadian Centre Activities ,medicine.drug - Abstract
Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (vegf) receptors 1, 2, 3, and platelet-derived growth factor receptors alpha (pdgfra) and beta (pdgfrb). Because angiogenesis is necessary for the growth and metastasis of solid tumours, and vegf is believed to have a pivotal role in that process, sunitinib treatment may have broad-spectrum clinical utility. In the present article, we discuss the biologic and clinical rationales that have recently led the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group to initiate four phase ii trials testing this agent in the following four different tumour types: relapsed diffuse large cell lymphoma, malignant pleural mesothelioma, locally advanced or metastatic cervical cancer and recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
- Published
- 2007
- Full Text
- View/download PDF
7. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients
- Author
-
Daniela Alexandru-Abrams, Michelle Paff, Daniela A. Bota, and Frank P.K. Hsu
- Subjects
Oncology ,KPS ,Epidemiology ,medicine.medical_treatment ,delayed-type hypersensitivity ,Review ,year ,EGFRVIII ,WHO ,Mice ,day ,Antineoplastic Combined Chemotherapy Protocols ,Cancer ,transforming growth factor beta ,Surveillance ,Brain Neoplasms ,Vaccination ,OS ,DTH ,major histocompatibility complex ,HLA ,Bevacizumab ,ErbB Receptors ,GAGE ,IL-12 ,5.1 Pharmaceuticals ,Medical Microbiology ,IL-10 ,Immunotherapy ,Development of treatments and therapeutic interventions ,National Cancer Institute of Canada ,medicine.medical_specialty ,Subunit ,TTP ,Dacarbazine ,Immunology ,Brain tumor ,World Health Organization ,Irinotecan ,GBM ,antigen-presenting cell ,Disease-Free Survival ,Ab ,human leukocyte antigen ,Grb2 ,Humans ,Progression-free survival ,CD25 ,Pharmacology ,Granulocyte-macrophage colony-stimulating factor ,prostaglandin E2 ,Epidermal Growth Factor ,glioblastoma ,A Complementary Trial of an Immunotherapy Vaccine against Tumor Specific EGRFvIII ,medicine.disease ,CD4 ,NCIC ,APC ,Cytotoxic T lymphocytes ,SEER ,TGF-b ,Brain Cancer ,Camptosar ,CTL ,Growth factor receptor-bound protein 2 ,rat sarcoma genes ,KLH ,MHC ,TMZ ,Glioblastoma ,BBB ,progression-free survival ,Treg cells ,Ras ,blood brain barrier ,temozolomide ,time to progression ,regulatory T cells ,PFS ,antibody ,CPT-11 ,vaccine ,Monoclonal ,Immunology and Allergy ,Humanized ,ACTIVATE ,Interferon gamma ,Vaccines ,G antigen gene family ,lipopolysaccharide ,Pharmacology and Pharmaceutical Sciences ,Chemoradiotherapy ,Interleukin-12 ,VEGF ,Interleukin-10 ,EORTC ,Blood-Brain Barrier ,6.1 Pharmaceuticals ,Vaccines, Subunit ,European Organization for Research and Treatment of Cancer ,PGE2 ,CNS ,MGMT ,medicine.drug ,Receptor ,LPS ,keyhole limpet hemocyanin ,overall survival ,brain ,therapies ,Biology ,Karnofsky performance status ,Antibodies, Monoclonal, Humanized ,cluster of differentiation 4 ,Cancer Vaccines ,Antibodies ,Immune system ,Rare Diseases ,Internal medicine ,and End Results Program ,Virology ,cluster of differentiation 25 ,medicine ,Temozolomide ,Animals ,O-6-methylguanine-DNA methyltransferase ,T helper type 2 cells ,IL-2 ,INF-g ,Neurosciences ,Evaluation of treatments and therapeutic interventions ,GM-CSF ,central nervous system ,Brain Disorders ,Orphan Drug ,TH2 cells ,Interleukin-2 ,Immunization ,Camptothecin ,Vascular endothelial growth factor ,The epidermal growth factor receptor variant III ,Glioblastoma Multiforme - Abstract
© 2014 Taylor & Francis Group, LLC. Glioblastoma Multiforme (GBM) is the most common type of brain tumor and it is uniformly fatal. The community standard of treatment for this disease is gross or subtotal resection of the tumor, followed by radiation and temozolomide. At recurrence bevacizumab can be added for increased progression free survival. Many challenges are encountered while trying to devise new drugs to treat GBM, such as the presence of the blood brain barrier which is impermeable to most drugs. Therefore in the past few years attention was turned to immunological means for the treatment of this devastating disease. EGFRvIII targeting has proven a good way to attack glioblastoma cells by using the immune system. Although in still in development, this approach holds the promise as a great first step toward immune-tailored drugs for the treatment of brain cancers.
- Published
- 2014
- Full Text
- View/download PDF
8. RESEARCH IN GENITOURINARY ONCOLOGY: THE CANADIAN URO-ONCOLOGY GROUP MULTIDISCIPLINARY MODEL.
- Author
-
Saad, Fred
- Subjects
- *
CANCER patients , *GENITOURINARY organ cancer , *ORGANS (Anatomy) , *MEDICAL research , *ONCOLOGY - Abstract
The article presents the research in genitourinary oncology conducted by the Canadian Uro-Oncology Group (CUOG) Multidisciplinary Model. CUOG has led a surgical wait times initiative, which led to recommendations in maximum wait times for patients with urological cancers. The CUOG model is being used as an example of success in clinical research, as Canadian investigators consistently perform extremely well in the quality and quantity of patients put on trials.
- Published
- 2008
- Full Text
- View/download PDF
9. Charting the NCIC's future: stakeholder support for identified options
- Author
-
Ashbury, F D, Iverson, Donald C, Shepherd, P J, Hachey, C, Ashbury, F D, Iverson, Donald C, Shepherd, P J, and Hachey, C
- Abstract
The National Cancer Institute of Canada (NCIC) conducted a survey of representatives of its stakeholder populations (members of the cancer research and control communities, past and present NCIC grantees, senior administrators in academic institutions, NCIC governing committee representatives and major partners) to get input on proposals to restructure the NCIC's research programs. The survey results demonstrate support for changes that are likely to significantly alter how the NCIC operates as well as the programs it sponsors. The results suggest support for increasing the percentage of NCIC funds allocated to the Individual Operating Grants area and for changing the NCIC's programs and operating procedures. While there was widespread support for an NCIC-sponsored regional development initiative, many issues remain unresolved, such as what type of cancer research to develop within the provinces.
- Published
- 1995
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.